GSK beat the numbers, but the real story was the guidance Proactive uses images sourced from Shutterstock A clean fourth-quarter beat pushed GSK ahead of its own medium-term targets. Yet management chose to set a deliberately modest bar for 2026, leaving investors to decide whether this is prudence or opportunity. At first glance, GSK PLC's (LSE:GSK, NYSE:GSK) fourth-quarter results look like exactly what the market ordered. Revenue came in ahead of expectations, earnings beat by a wide margin, and the gr ...